IPO Coimbra invests 4.5 million in unique technology in the country – Daily News – Lisbon

treatments Efficiencies and patient welfare justify the investment in the equipment that will be available to all Portuguese users

the Portuguese Institute of Oncology (IPO) of Coimbra invested EUR 4.5 million in equity in a single technology in the country for the treatment of cancer, particularly tumors treated by external radiation to the brain.

the new tomoterapia unit allows, according to the president of the IPO of Coimbra, Manuel António Silva, a treatment “more efficiently and with better results for the patient,” and its creation “deserved the agreement” of professionals radiotherapy of the institution, he said.

According to a press note from the IPO, innovative technology enables the dose of radiation is directed to the target tumor, “saving significantly each of the organs at risk that may be in your immediate vicinity and the consistent, efficient and reliable administration of the same dose distribution. “

” the duration of each shortens treatment session significantly, with increases not only efficiency, and convenience and well-being the patient who fails to require long times to immobilization and postural rigidity, “reads the same information.

” This new plant strengthens the installed capacity in radiotherapy in the NHS [National Health Service] or innovation that involves both the possibility of setting up as a reference whenever deemed treatment by ionizing radiation “it said.

Manuel António Silva said, however, that the innovative technology” is available to everyone in Portugal, “not only for the patients in the IPO of Coimbra.

” we already do in other areas, we are open to such collaboration. In the National Health Service communication between institutions is very positive, “he assured.

The new treatment plant is part of the ongoing investment plan in the IPO of Coimbra, an institution that integrates the platform” more nuanced “of Referencing Hospital Oncology network, “which gave it the responsibility of the diagnosis and treatment of tumors, regardless of their impact, in particular those which require more complex techniques and technology and less vulgarized,” argues the press release.